Literature DB >> 34176750

Role of ureterocalicostomy in management of giant hydronephrosis in children in contemporary practice: Indications, outcomes and challenges.

M S Ansari1, Nayab Danish2, Priyank Yadav3, Vinay N Kaushik4, Shitangsu Kakoti5, Abhay Kumar6, Ravi Banthia7, Aneesh Srivastava8.   

Abstract

INTRODUCTION: Given the rarity of giant hydronephrosis (GH), ideal surgical approach, assessment of drainage after surgery, expected improvement in renal function and morphological changes in the kidney on follow up have not been studied extensively. The aim of this study was to investigate the role of ureterocalicostomy (UC) in unilateral GH with respect to its current indications, outcomes and the challenges associated with it.
MATERIALS AND METHODS: We retrospectively analysed data of 25 children (up to the age of 18 years) who underwent UC between January 2008 and January 2019 using open, laparoscopic or robotic-assisted approach. Preoperative workup included ultrasonography for pelvic anteroposterior diameter (APD) and cortical thickness (CT), and diuretic scan for split renal function (SRF) and drainage. Patients were followed with ultrasonography and diuretic renal scan at 3 months, after further 6 month and then annually.
RESULTS: The median age was 7 years and median follow-up was 22 months. Eight children underwent UC as salvage procedure while 17 children underwent UC as an upfront procedure. APD declined significantly (p < 0.001) and CT improved significantly (p = 0.009) after surgery. The drainage as well as SRF did not change significantly after surgery. Four children developed flank pain after stent removal; one required a redo-ureterocalicostomy for anastomotic stricture while another required balloon dilatation of the anastomosis. Two children responded to prolonged stenting for 2 months. DISCUSSION: Ultrasonography (APD, CT), Diuretic renal scan (SRF and drainage pattern) are used to monitor HDN. APD is particularly important in GH because the diuretic renogram invariably shows an obstructive drainage owing to the large volume of the pelvicalyceal system. Similar to previous studies in literature, we too reported a decline in APD. CT improved in our study, however, the drainage pattern as well as SRF did not change significantly (Figure). Diuretic scan in isolation was not sufficient to predict failure. A combination of ultrasonographic and diuretic scan parameters were useful for follow up and for detection of failure. The success rate in our study was 92%. Chief limitations of our study were retrospective nature and lack of comparison with pyeloplasty. Moreover, some cases were performed with minimal invasive techniques, so the study group was heterogenous.
CONCLUSIONS: UC offers excellent outcome in children with GH due to primary as well as secondary UPJO. Isolated ultrasonographic or diuretic renogram parameters are not sufficient to predict failure and a combination of them should be used for follow up after UC.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Child; Follow-up studies; Hydronephrosis; Kidney pelvis/ abnormalities; Treatment outcome

Mesh:

Year:  2021        PMID: 34176750     DOI: 10.1016/j.jpurol.2021.06.007

Source DB:  PubMed          Journal:  J Pediatr Urol        ISSN: 1477-5131            Impact factor:   1.830


  2 in total

1.  Giant hydronephrosis presented as a huge abdominal mass in a 16-year-old female: a case report.

Authors:  Waleed Aljbri; Faisal Ahmed; Saif Ghabisha; Menawar Dajenah; Ebrahim Al-Shami; Qasem Alyhari; Fawaz Mohammed
Journal:  Pan Afr Med J       Date:  2022-04-12

2.  Laparoscopic and robot-assisted ureterocalicostomy for treatment of primary and recurrent pelvi-ureteric junction obstruction in children: a multicenter comparative study with laparoscopic and robot-assisted Anderson-Hynes pyeloplasty.

Authors:  Ciro Esposito; Thomas Blanc; Dariusz Patkowski; Pedro José Lopez; Lorenzo Masieri; Anne-Francoise Spinoit; Maria Escolino
Journal:  Int Urol Nephrol       Date:  2022-07-21       Impact factor: 2.266

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.